EP4010004A4 - Compositions and methods for modulation of gene expression - Google Patents
Compositions and methods for modulation of gene expression Download PDFInfo
- Publication number
- EP4010004A4 EP4010004A4 EP20851042.0A EP20851042A EP4010004A4 EP 4010004 A4 EP4010004 A4 EP 4010004A4 EP 20851042 A EP20851042 A EP 20851042A EP 4010004 A4 EP4010004 A4 EP 4010004A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- modulation
- compositions
- methods
- gene expression
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962884028P | 2019-08-07 | 2019-08-07 | |
US201962898434P | 2019-09-10 | 2019-09-10 | |
US201962937011P | 2019-11-18 | 2019-11-18 | |
PCT/US2020/045174 WO2021026336A2 (en) | 2019-08-07 | 2020-08-06 | Compositions and methods for modulation of gene expression |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4010004A2 EP4010004A2 (en) | 2022-06-15 |
EP4010004A4 true EP4010004A4 (en) | 2023-09-13 |
Family
ID=74502663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20851042.0A Pending EP4010004A4 (en) | 2019-08-07 | 2020-08-06 | Compositions and methods for modulation of gene expression |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4010004A4 (en) |
WO (1) | WO2021026336A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022032397A1 (en) * | 2020-08-14 | 2022-02-17 | The Governing Council Of The University Of Toronto | Krab fusion repressors and methods and compositions for repressing gene expression |
CN114195902B (en) * | 2021-10-18 | 2023-06-20 | 翌圣生物科技(上海)股份有限公司 | Recombinant protein structural domain enhanced TET enzyme and whole genome DNA methylation detection method |
CN114600837B (en) * | 2022-04-15 | 2023-05-02 | 润康生物医药(苏州)有限公司 | Animal model for granulocytopenia, construction method thereof and application of ikzf1 and cmyb in construction model |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012104729A1 (en) * | 2011-02-02 | 2012-08-09 | Ulla Bonas | Modular dna-binding domains and methods of use |
WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
WO2017069958A2 (en) * | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6919204B2 (en) * | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
AU2012340213B2 (en) * | 2011-11-16 | 2017-12-07 | Sangamo Therapeutics, Inc. | Modified DNA-binding proteins and uses thereof |
RS60838B1 (en) * | 2012-08-29 | 2020-10-30 | Sangamo Therapeutics Inc | Methods and compositions for treatment of a genetic condition |
PT3068881T (en) * | 2013-11-13 | 2019-05-31 | Childrens Medical Center | Nuclease-mediated regulation of gene expression |
WO2016019144A2 (en) * | 2014-07-30 | 2016-02-04 | Sangamo Biosciences, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
EP3781193A4 (en) * | 2018-04-18 | 2022-01-26 | Altius Institute For Biomedical Sciences | Animal pathogen-derived polypeptides and uses thereof for genetic engineering |
-
2020
- 2020-08-06 WO PCT/US2020/045174 patent/WO2021026336A2/en unknown
- 2020-08-06 EP EP20851042.0A patent/EP4010004A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012104729A1 (en) * | 2011-02-02 | 2012-08-09 | Ulla Bonas | Modular dna-binding domains and methods of use |
WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
WO2017069958A2 (en) * | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
Also Published As
Publication number | Publication date |
---|---|
WO2021026336A2 (en) | 2021-02-11 |
EP4010004A2 (en) | 2022-06-15 |
WO2021026336A3 (en) | 2021-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3510152A4 (en) | Methods and compositions for modulating gene expression | |
EP3576737A4 (en) | Compositions and methods of modulating short-chain dehydrogenase activity | |
EP3962296A4 (en) | Cannabinoid compositions and methods of using | |
EP3573623A4 (en) | Compositions and methods for inhibition of factor xii gene expression | |
EP3781705A4 (en) | Compositions and methods for gene editing | |
EP4054621A4 (en) | Compositions and methods for rna-encoded dna-replacement of alleles | |
EP4010004A4 (en) | Compositions and methods for modulation of gene expression | |
EP3883577A4 (en) | Compositions and methods of modulating short-chain dehydrogenase activity | |
EP3906240A4 (en) | Compositions and methods for modulating hair growth | |
EP3761972A4 (en) | Bioreactive compositions and methods of use thereof | |
EP3765058A4 (en) | Methods and compositions for inducible expression of neurotrophic factors | |
EP3946374A4 (en) | Oligonucleotide-based modulation of c9orf72 | |
EP3976798A4 (en) | Compositions and methods for selective gene regulation | |
EP3941927A4 (en) | Compositions and methods for modification of target molecules | |
EP3982949A4 (en) | Inhibitors of sarm1 | |
EP3980011A4 (en) | Inhibitors of sarm1 | |
EP3980004A4 (en) | Tributyrin compositions and methods therefor | |
EP3931305A4 (en) | Compositions and methods for long term culture of hepatocytes | |
EP4003246A4 (en) | Compositions and methods for treatment of presbyopia | |
EP3841114A4 (en) | Methods and compositions for rna expression of myc inhibitors | |
EP3976811A4 (en) | Metabolomic characterization of microorganisms | |
EP3950961A4 (en) | Application of kdm5a gene and atrx gene | |
EP3987024A4 (en) | Compositions and methods for improved gene editing | |
EP4009962A4 (en) | Compositions of trofinetide | |
EP3972986A4 (en) | Methods and compositions for irreversible enzyme inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220210 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230814 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 9/22 20060101ALI20230808BHEP Ipc: C07K 14/705 20060101ALI20230808BHEP Ipc: C07K 14/725 20060101ALI20230808BHEP Ipc: C12N 15/85 20060101ALI20230808BHEP Ipc: C12N 15/00 20060101ALI20230808BHEP Ipc: C07K 19/00 20060101ALI20230808BHEP Ipc: C07K 14/195 20060101ALI20230808BHEP Ipc: A61K 38/00 20060101AFI20230808BHEP |